Securities code: 688488 securities abbreviation: Jiangsu Aidea Pharmaceutical Co.Ltd(688488) Announcement No.: 2022-007 Jiangsu Aidea Pharmaceutical Co.Ltd(688488)
Announcement on applying for bank credit line in 2022
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
Jiangsu Aidea Pharmaceutical Co.Ltd(688488) (hereinafter referred to as "the company" or " Jiangsu Aidea Pharmaceutical Co.Ltd(688488) ") held the 21st Meeting of the first board of directors on January 19, 2022, deliberated and adopted the proposal on applying for bank credit line in 2022. The details are hereby announced as follows:
In order to meet the needs of the company's operation and business development, the company plans to apply for a comprehensive credit line with a total amount of no more than RMB 180 million from China Construction Bank Corporation(601939) Yangzhou Branch and Bank Of Ningbo Co.Ltd(002142) Nanjing branch by credit in 2022. The credit products include but are not limited to working capital loan, bank acceptance bill, letter of guarantee, letter of credit, etc. The credit line applied by the company to the bank shall be subject to the amount actually approved by the bank. The credit period is 1 year. The credit line can be recycled within the credit period. The specific financing amount is determined within the comprehensive credit line according to the actual capital demand of the company.
Remarks on the credit line applied by the applicant's credit granting bank
(10000 yuan)
China Construction Bank Corporation(601939) Yangzhou Branch 10000 credit method
Jiangsu Aidea Pharmaceutical Co.Ltd(688488) Bank Of Ningbo Co.Ltd(002142) Nanjing Branch 8000 credit method
In order to improve work efficiency, the board of directors agreed to authorize the chairman or the person authorized by the chairman to handle relevant credit and financing business with the above financial institutions within the above line, and sign relevant agreements on behalf of the company. The validity period of the authorization is one year from the date of deliberation and approval by the board of directors.
It is hereby announced.
Jiangsu Aidea Pharmaceutical Co.Ltd(688488) board of directors January 20, 2022
